Implant Sciences Aims At Orthopedic, Brachytherapy, Stent Markets With IPO
This article was originally published in The Gray Sheet
Executive Summary
Implant Sciences Corp., currently developing a method for embedding radioactivity into coronary stents in partnership with Guidant, is looking to raise $6-7 mil. in an initial public offering this spring, according to a prospectus filed Feb. 10 with the Securities and Exchange Commission.
You may also be interested in...
Biomet Begins Ceramic Hip Implant Study, As Stryker Nears Panel Review
Biomet plans to evaluate its ceramic-on-ceramic hip prosthesis in a 100-patient clinical study that is scheduled for completion in mid-2002, company officials report.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.